

ASX Announcement

8 Apr 2008

Cytopia presentation on JAK2 inhibitor at American Association for Cancer Research

Cytopia Limited (ASX:CYT) today announced that it is presenting data on its JAK2 inhibitor at the American Association for Cancer Research Annual Meeting being held in San Diego, California. The meeting involves approximately 17,000 participants from around the world to discuss new and significant discoveries in cancer research.

The poster, titled "A Novel JAK2 inhibitor for the treatment of myeloproliferative disorders" (Abstract # 4880), will be presented to the meeting by Dr Emmanuelle Fantino, Head, Biology on 15 April 2008 from 1:00 – 5:00pm.

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer. Cytopia conducts its research and development via subsidiaries based in Melbourne, Australia and New York and specialises in discovering new molecules that can inhibit enzymes known as kinases, an exciting new class of drugs.

Website: www.cytopia.com.au

Enquiries:

Mr Andrew Macdonald
Chief Executive Officer
T: +61 3 9208 4232
andrew.macdonald@cytopia.com.au

Dr Chris Burns
Director, Research
T: +61 3 9208 4235
chris.burns@cytopia.com.au